Association of IL-10 polymorphism with severity of illness in community acquired pneumonia

被引:140
作者
Gallagher, PM
Lowe, G
Fitzgerald, T
Bella, A
Greene, CM
McElvaney, NG
O'Neill, SJ [1 ]
机构
[1] Beaumont Hosp, Royal Coll Surg Ireland, Educ & Res Ctr, Dept Med,Div Resp Res, Dublin 9, Ireland
[2] Royal Coll Surgeons Ireland, Dept Epidemiol, Dublin 2, Ireland
关键词
D O I
10.1136/thorax.58.2.154
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The influence of genetic polymorphisms of interleukin (IL)-10, tumour necrosis factor (TNF)-alpha, and IL-6 gene promoters on severity of systemic inflammatory response syndrome (SIRS) associated with community acquired pneumonia (CAP) was studied. Methods: Using PCR-RFLP analysis we analysed a - 1082G/A single nucleotide polymorphism (SNP) of the anti-inflammatory IL-10 gene, a -308G/A SNP of the pro-inflammatory TNF-alpha gene and a -174G/C SNP of the IL-6 gene. Illness severity was stratified according to SIRS score, calculated by presence of up to four physiological indices: temperature, white blood cell count, heart rate and respiratory rate (non-SIRS, SIRS 2, SIRS 3, and SIRS 4). Results: A statistically significant stepwise increase in frequency of the IL-10 G allele, associated with higher expression of the gene, was observed in patients with increasing severity of illness from non-SIRS (n=19) to SIRS 2 (n=17), SIRS 3 (n=33) and SIRS 4 (n=24). This was primarily due to a higher frequency of the GG genotype with increasing severity from non-SIRS through to SIRS 4. IL-10 G allele frequency was also increased in patients who died as a result of CAP (n=11) compared with CAP survivors (n=82) (p=0.01). No association was seen between the TNF-alpha -308G/A and IL-6 -174G/C SNPs and disease. Additionally, no interaction between all three SNP genotypes and disease severity was observed. Conclusions: A polymorphism affecting IL-10 expression may influence the severity of illness in patients with CAP.
引用
收藏
页码:154 / 156
页数:3
相关论文
共 9 条
[1]
AMERICAN-COLLEGE OF CHEST PHYSICIANS SOCIETY OF CRITICAL CARE MEDICINE CONSENSUS CONFERENCE - DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ ;
ABRAMS, JH ;
BERNARD, GR ;
BIONDI, JW ;
CALVIN, JE ;
DEMLING, R ;
FAHEY, PJ ;
FISHER, CJ ;
FRANKLIN, C ;
GORELICK, KJ ;
KELLEY, MA ;
MAKI, DG ;
MARSHALL, JC ;
MERRILL, WW ;
PRIBBLE, JP ;
RACKOW, EC ;
RODELL, TC ;
SHEAGREN, JN ;
SILVER, M ;
SPRUNG, CL ;
STRAUBE, RC ;
TOBIN, MJ ;
TRENHOLME, GM ;
WAGNER, DP ;
WEBB, CD ;
WHERRY, JC ;
WIEDEMANN, HP ;
WORTEL, CH .
CRITICAL CARE MEDICINE, 1992, 20 (06) :864-874
[2]
Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus (vol 49, pg 635, 1997) [J].
Eskdale, J ;
Wordsworth, P ;
Bowman, S ;
Field, M ;
Gallagher, G .
TISSUE ANTIGENS, 1997, 50 (06) :699-699
[3]
The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis [J].
Fishman, D ;
Faulds, G ;
Jeffery, R ;
Mohamed-Ali, V ;
Yudkin, JS ;
Humphries, S ;
Woo, P .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) :1369-1376
[4]
Circulating interleukin 6 and interleukin 10 in community acquired pneumonia [J].
Glynn, P ;
Coakley, R ;
Kilgallen, I ;
Murphy, N ;
O'Neill, S .
THORAX, 1999, 54 (01) :51-55
[5]
The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription [J].
Kroeger, KM ;
Carville, KS ;
Abraham, LJ .
MOLECULAR IMMUNOLOGY, 1997, 34 (05) :391-399
[6]
THE NATURAL-HISTORY OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) - A PROSPECTIVE-STUDY [J].
RANGELFRAUSTO, MS ;
PITTET, D ;
COSTIGAN, M ;
HWANG, T ;
DAVIS, CS ;
WENZEL, RP .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (02) :117-123
[7]
Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock [J].
Sfeir, T ;
Saha, DC ;
Astiz, M ;
Rackow, EC .
CRITICAL CARE MEDICINE, 2001, 29 (01) :129-133
[8]
An investigation of polymorphism in the interleukin-10 gene promoter [J].
Turner, DM ;
Williams, DM ;
Sankaran, D ;
Lazarus, M ;
Sinnott, PJ ;
Hutchinson, IV .
EUROPEAN JOURNAL OF IMMUNOGENETICS, 1997, 24 (01) :1-8
[9]
Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: Sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13 [J].
vanderPoll, T ;
Malefyt, RD ;
Coyle, SM ;
Lowry, SF .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (01) :118-122